Literature DB >> 16357142

Negative regulation of TSC1-TSC2 by mammalian D-type cyclins.

Sima J Zacharek1, Yue Xiong, Stuart D Shumway.   

Abstract

The metazoan cell cycle is driven by the timely and composite activities of cyclin-dependent kinases (CDKs). Among these, cyclin D- and cyclin E-dependent kinases phosphorylate the pRb family proteins during G(1) phase of the cell cycle and thereby advance cells beyond the restriction point. Increasing evidence suggests that cyclin D-dependent kinases might affect events other than Rb pathway-mediated entry into S phase, such as accumulation of cell mass. However, little is known about cyclin D activity toward Rb-independent pathway(s) or non-pRb substrates. In this article, we show that the tumor suppressor TSC2 is a cyclin D binding protein. Coexpression of cyclin D1-CDK4/6 in cultured cells leads to increased phosphorylation and decreased detection of both TSC2 and TSC1, and promotes the phosphorylation of the mTOR substrates, 4E-BP1 and S6K1, two key effectors of cell growth that are negatively regulated by the TSC1-TSC2 complex. At the cellular level, ectopic expression of cyclin D1 restores the cell size decrease caused by TSC1-TSC2 expression. Intriguingly, down-regulation of TSC proteins was also observed by the expression of a mutant cyclin D1 that is unable to bind to CDK4/6, or by the coexpression of cyclin D1 with either an INK4 inhibitor or with catalytically inactive CDK6, indicating that cyclin D may regulate TSC1-TSC2 independently of CDK4/6. Together, these observations suggest that mammalian D-type cyclins participate in cell growth control through negative regulation of TSC1-TSC2 function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357142     DOI: 10.1158/0008-5472.CAN-05-2236

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

2.  Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.

Authors:  Yana Pikman; Gabriela Alexe; Giovanni Roti; Amy Saur Conway; Andrew Furman; Emily S Lee; Andrew E Place; Sunkyu Kim; Chitra Saran; Rebecca Modiste; David M Weinstock; Marian Harris; Andrew L Kung; Lewis B Silverman; Kimberly Stegmaier
Journal:  Clin Cancer Res       Date:  2016-11-09       Impact factor: 12.531

Review 3.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

4.  CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.

Authors:  Andreas M Heilmann; Rushika M Perera; Veronika Ecker; Brandon N Nicolay; Nabeel Bardeesy; Cyril H Benes; Nicholas J Dyson
Journal:  Cancer Res       Date:  2014-07-01       Impact factor: 12.701

5.  MEK drives cyclin D1 hyperelevation during geroconversion.

Authors:  O V Leontieva; Z N Demidenko; M V Blagosklonny
Journal:  Cell Death Differ       Date:  2013-07-12       Impact factor: 15.828

6.  WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase.

Authors:  Jian Hu; Sima Zacharek; Yizhou Joseph He; Hyun Lee; Stuart Shumway; Robert J Duronio; Yue Xiong
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

7.  Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Authors:  Shom Goel; Qi Wang; April C Watt; Sara M Tolaney; Deborah A Dillon; Wei Li; Susanne Ramm; Adam C Palmer; Haluk Yuzugullu; Vinay Varadan; David Tuck; Lyndsay N Harris; Kwok-Kin Wong; X Shirley Liu; Piotr Sicinski; Eric P Winer; Ian E Krop; Jean J Zhao
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

Review 8.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

9.  Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.

Authors:  Edoardo Missiaglia; Irene Dalai; Stefano Barbi; Stefania Beghelli; Massimo Falconi; Marco della Peruta; Lorenzo Piemonti; Gabriele Capurso; Alessia Di Florio; Gianfranco delle Fave; Paolo Pederzoli; Carlo M Croce; Aldo Scarpa
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

Review 10.  Untapped Reserves: Controlling Primordial Follicle Growth Activation.

Authors:  Amanda Kallen; Alex J Polotsky; Joshua Johnson
Journal:  Trends Mol Med       Date:  2018-02-13       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.